{"id":50644,"date":"2022-11-09T08:03:08","date_gmt":"2022-11-09T07:03:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/"},"modified":"2022-11-09T08:03:08","modified_gmt":"2022-11-09T07:03:08","slug":"beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/","title":{"rendered":"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nBeckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023.\n<\/li>\n<li>\nELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, under clinical development for depression.\n<\/li>\n<li>\nELE-101 is the second clinical-stage psychedelic compound in Beckley Psytech\u2019s portfolio alongside BPL-003, the company\u2019s lead candidate for upcoming MHRA-approved Phase IIa studies in depression and Alcohol Use Disorder (AUD).\n<\/li>\n<\/ul>\n<p>OXFORD, England&#8211;(BUSINESS WIRE)&#8211;Beckley Psytech, a clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announced that the first participant has been dosed in its Phase I clinical trial (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05434156&amp;esheet=52964080&amp;newsitemid=20221108005986&amp;lan=en-US&amp;anchor=NCT05434156&amp;index=1&amp;md5=a7eea4ac63e0335d3e25fbe5a46d56b3\" rel=\"nofollow noopener\" shape=\"rect\">NCT05434156<\/a>) of ELE-101, a novel, short-acting psychedelic compound which is intended to serve as a possible treatment for depression.\n<\/p>\n<p>\nThe trial is a double-blind, randomised, placebo-controlled study designed to assess the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) and subjective drug intensity (SDI) of single ascending intravenous doses of ELE-101 in up to 60 healthy adult participants. Full results of the study are expected in H1 2023, and blinded data will be used to help design the Phase IIa study, with initiation also planned for H1 2023.\n<\/p>\n<p>\nELE-101 was added to Beckley Psytech\u2019s portfolio following the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beckleypsytech.com%2Fposts%2Fbeckley-psytech-acquires-eleusis-therapeutics&amp;esheet=52964080&amp;newsitemid=20221108005986&amp;lan=en-US&amp;anchor=acquisition+of+Eleusis+Therapeutics+Limited&amp;index=2&amp;md5=1ca388b65988e995efd07820f744a5c1\" rel=\"nofollow noopener\" shape=\"rect\">acquisition of Eleusis Therapeutics Limited<\/a> in October 2022. The team is confident that the proprietary intravenous formulation of psilocin, the active metabolite of psilocybin, has the potential to address some of the observed limitations of oral psilocybin &#8211; such as long duration of action and variability in patients\u2019 responses &#8211; and is designed to deliver a shorter, more consistent and more controllable experience in patients, with fewer side effects.\n<\/p>\n<p>\nCommenting on the initiation of the Phase I study, Cosmo Feilding Mellen, CEO of Beckley Psytech, said: <i>\u201cThis is an important milestone for Beckley Psytech and demonstrates our commitment to positively disrupt the way depression and other neuropsychiatric conditions are treated. It also reflects our commitment to explore novel, shorter-acting formulations of psychedelic compounds which, we believe, will provide a more accessible treatment option with a lower burden on both patients and healthcare systems. We are optimistic about the potential of ELE-101 and are looking forward to evaluating the compound in future studies.\u201d<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<b>-Ends-<\/b>\n<\/p>\n<p>\n<b>Beckley Psytech &#8211; <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.beckleypsytech.com&amp;esheet=52964080&amp;newsitemid=20221108005986&amp;lan=en-US&amp;anchor=www.beckleypsytech.com&amp;index=3&amp;md5=de4af8d2b0d3152541466ff8497e35d4\" rel=\"nofollow noopener\" shape=\"rect\">www.beckleypsytech.com<\/a><\/b>\n<\/p>\n<p>\nBeckley Psytech is a private, clinical-stage biotechnology company dedicated to improving the lives of people suffering from neuropsychiatric disorders by developing a pipeline of psychedelic compounds into licensed pharmaceutical medicines. The Company\u2019s most advanced programmes are focused on the development of BPL-003, an intranasal synthetic formulation of 5-MeO-DMT, for treatment resistant depression (TRD) and ELE-101, an intravenous synthetic formulation of psilocin, the active metabolite of psilocybin, for major depressive disorder (MDD). Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the Beckley Foundation, we combine world-leading psychedelic science with deep drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden these conditions have on individuals and society.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nFor more information please contact:\n<\/p>\n<p>\nBeckley Psytech<br \/>\n<br \/>Cosmo Feilding Mellen<br \/>\n<br \/>Chief Executive Officer<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x69;&#110;&#x66;&#111;&#x40;&#98;&#x65;&#99;&#x6b;&#108;&#x65;&#121;&#x70;&#115;&#x79;&#116;&#x65;&#99;&#x68;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#110;&#102;o&#x40;&#x62;&#101;c&#x6b;&#x6c;&#101;y&#x70;&#x73;&#121;t&#x65;&#x63;&#104;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<p>\nCommunications<br \/>\n<br \/>FTI Consulting<br \/>\n<br \/>Ben Atwell \/ Mike Trace<br \/>\n<br \/>+44 (0)20 3727 1000<br \/>\n<br \/><a target=\"_blank\" href=\"mail&#116;&#111;&#58;&#98;&#101;&#99;&#107;&#x6c;&#x65;&#x79;&#x70;&#x73;&#x79;&#x74;&#x65;&#x63;h&#64;ft&#105;&#99;&#111;&#110;&#115;&#117;&#108;&#x74;&#x69;&#x6e;&#x67;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x62;&#x65;&#x63;&#107;&#108;ey&#x70;&#x73;&#x79;&#x74;&#101;&#99;h&#64;&#x66;&#x74;&#x69;&#99;&#111;&#110;su&#x6c;&#x74;&#x69;&#110;&#103;&#46;c&#x6f;&#x6d;<\/a>\n<\/p>\n<p>\nInvestor Relations<br \/>\n<br \/>LifeSci Advisors<br \/>\n<br \/>Guillaume van Renterghem<br \/>\n<br \/>+41 76 735 01 31<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;o:&#x67;&#x76;&#x61;&#x6e;&#114;&#101;nt&#x65;&#x72;&#x67;&#104;&#101;&#109;&#64;l&#x69;&#x66;&#x65;&#115;&#99;ia&#x64;&#x76;&#x69;&#x73;&#111;&#114;s&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">gvanrentergh&#101;&#109;&#64;&#108;&#105;&#102;&#101;&#115;&#99;&#105;&#97;&#100;&#118;&#105;&#115;&#x6f;&#x72;&#x73;&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023. ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, under clinical development for depression. ELE-101 is the second clinical-stage psychedelic compound in Beckley Psytech\u2019s portfolio alongside BPL-003, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50644","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023. ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, under clinical development for depression. ELE-101 is the second clinical-stage psychedelic compound in Beckley Psytech\u2019s portfolio alongside BPL-003, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-09T07:03:08+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin\",\"datePublished\":\"2022-11-09T07:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\\\/\"},\"wordCount\":546,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\\\/\",\"name\":\"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-09T07:03:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/","og_locale":"en_US","og_type":"article","og_title":"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin - Pharma Trend","og_description":"Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023. ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, under clinical development for depression. ELE-101 is the second clinical-stage psychedelic compound in Beckley Psytech\u2019s portfolio alongside BPL-003, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-09T07:03:08+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin","datePublished":"2022-11-09T07:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/"},"wordCount":546,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/","url":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/","name":"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-09T07:03:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50644"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50644\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}